Skip to content
Clinical Trials – home
Not yet recruitingRare disease

Study of Bexmarilimab with Azacitidine versus Placebo with Azacitidine in Treatment‑Naïve Higher‑Risk Myelodysplastic Syndrome Patients

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

Higher-risk Myelodysplastic Syndrome (HR-MDS) is a condition where the bone marrow makes abnormal blood cells, leading to low blood counts and a higher chance of turning into leukemia. In this trial, participants receive a combination of bexmarilimab, given by IV infusion, together with the chemotherapy drug azacitidine. Some participants receive a matching placebo plus azacitidine instead of the study drug.

The study aims to find the best dose of bexmarilimab when used with azacitidine. Participants are randomly assigned to one of the two groups, and neither the participants nor the doctors know which group they are in (double‑blind). Treatments are given in cycles that repeat every few weeks for several months, with regular clinic visits for infusions and safety checks.

During the trial, doctors watch for how well the blood counts improve and for any side effects, using standard criteria that describe remission and serious adverse events. Blood samples are taken to see how the drug behaves in the body, and patients are asked about their quality of life, such as need for transfusions or hospital stays.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Baseline Evaluation

    On the first day after joining the trial, a complete medical evaluation is performed. This includes blood tests, bone‑marrow examination, and other examinations needed to confirm eligibility and to record the starting condition of higher‑risk myelodysplastic syndrome (HR‑MDS).

    The results are used as a reference point for all future assessments during the study.

  2. Step 2

    Start of Treatment

    The patient receives the study medication together with azacitidine. Azacitidine is given according to the schedule defined in the trial protocol.

    If assigned to the active arm, the patient receives bexmarilimab as an intravenous (IV) infusion at a dose of 3 mg per kilogram of body weight (3 mg/kg). If assigned to the control arm, the patient receives an IV infusion of 0.9 % sodium chloride solution, which serves as a placebo.

  3. Step 3

    Repeated Treatment Cycles

    The combination of azacitidine and either bexmarilimab or placebo is repeated in cycles. Each cycle follows the timing specified in the protocol, typically every four weeks.

    During each cycle, azacitidine is administered on the days required by the protocol, and the IV infusion of bexmarilimab or placebo is given on the designated day of the cycle.

  4. Step 4

    Safety Monitoring Visits

    Before every infusion, the patient attends a clinic visit for safety checks. Blood samples are taken to monitor blood counts and organ function, and any symptoms are recorded.

    The study team evaluates whether any adverse events (side effects) have occurred and determines if dose adjustments are needed.

  5. Step 5

    Response Assessments at 3 and 6 Months

    At approximately three months and again at six months after the first treatment, a formal evaluation is performed to assess the disease response.

    Doctors review blood and bone‑marrow results to determine whether a complete remission, partial remission, or other response has been achieved, using internationally accepted criteria.

  6. Step 6

    Continuation of Treatment

    If the disease does not progress and side effects remain manageable, the patient continues to receive treatment cycles until one of the following occurs: disease progression, unacceptable toxicity, withdrawal from the study, or the predefined end of the trial period.

  7. Step 7

    Final Study Evaluation

    When treatment stops, a final set of assessments is performed. These include overall survival status, any remaining adverse events, and a summary of all response data collected during the trial.

    The information is used to help determine the recommended dose of bexmarilimab for future studies.

Who can join the trial?

13 criteria

  • Provide written informed consent (a signed agreement that you understand the study and agree to join).
  • Be willing and able to follow all study procedures and attend follow‑up visits.
  • Be at least 18 years old.
  • Have a new diagnosis of myelodysplastic syndrome (MDS) that is confirmed by looking at the shape of cells (morphologically confirmed) and classified as higher‑risk MDS (HR‑MDS) according to the 2022 World Health Organization guidelines.
  • Be categorized as moderate‑high, high, or very high risk by the International Prognostic Scoring System–Molecular and have less than 20% bone marrow blasts (immature cells) on the screening bone‑marrow test.
  • Be eligible to receive the medicine azacitidine as used locally and be willing to start this treatment as part of the trial.
  • Have an Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 2 (a measure of how well you can carry out daily activities, where 0 means fully active and 2 means up and about more than half of the day).
  • Have a life expectancy of at least 3 months (expected to live at least three more months).
  • Show adequate organ function, including:
    • Creatinine clearance ≥ 30 mL/min using the Cockcroft‑Gault formula (a test of kidney function).
    • Indirect (unconjugated) bilirubin ≤ 1.5 times the normal upper limit (unless you have Gilbert’s syndrome, in which case it must be < 3 times the normal limit). Bilirubin is a waste product processed by the liver.
    • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 3 times the normal upper limit (these are enzymes that indicate liver health).
    • Have a baseline leukocyte count (white blood cell count) of less than 20 × 10⁹/L; using the medication hydroxycarbamide is allowed to help meet this requirement.
    • If you are a woman who could become pregnant, you must have a negative pregnancy test and agree to follow the study’s contraception rules; your partner must also agree to use contraception if you could become pregnant.

Who cannot join the trial?

19 criteria

  • You have previously been diagnosed with acute myeloid leukemia (AML), have disease that changed into AML, or have a type of myelodysplastic syndrome (MDS) that is not covered by this study, such as MDS that came from other blood disorders, overlap conditions like chronic myelomonocytic leukemia, advanced myelofibrosis (grade 3 or higher), or severe autoimmune destruction of red blood cells.
  • You have an active autoimmune disease that needs systemic medicines or a dose of prednisone (a steroid) of 10 mg per day or more within the two weeks before the first dose; only creams, inhalers, or eye drops are allowed.
  • You have serious liver problems, such as very poor liver function (Child‑Pugh C), liver enzymes (AST or ALT) more than three times the normal limit, or high bilirubin levels that exceed the study limits, or you have chronic ulcers that are likely to become infected.
  • You received cancer treatments that are not for MDS (or investigational drugs) too recently—for example, intravenous chemotherapy less than 21 days ago, oral small‑molecule drugs less than 14 days (or less than five drug half‑lives) ago, or other immunotherapy less than four weeks ago.
  • You have another cancer that is still active, getting worse, or needed systemic treatment within the past two years, except for non‑melanoma skin cancers or early‑stage cancers that were fully removed.
  • You have uncontrolled HIV infection, or active hepatitis B or C with a high amount of virus in your blood; controlled infections on stable treatment may be allowed.
  • You are pregnant or are breastfeeding.
  • You have already received the study drug bexmarilimab before.
  • You have a medical, psychiatric, or substance‑use condition that the doctor thinks could prevent you from giving proper consent, following the study plan, or affect the study results.
  • You are allergic (hypersensitive) to drugs similar to immunotherapy or to any of the inactive ingredients (excipients) in the study medication.
  • You had major surgery within four weeks before the first day of treatment.
  • You are considered a suitable candidate for an immediate allogeneic hematopoietic stem cell transplant (a donor blood‑forming stem cell transplant) at the time of screening.
  • Your blood or bone‑marrow contains 20 % or more immature cells (blasts) or you have a myeloid sarcoma, which is a solid tumor of the same disease outside the bone marrow.
  • You do not have required genetic testing results (cytogenetics) or you have a normal chromosome pattern when your blast count is less than 5 %.
  • You have already received disease‑changing treatments for MDS, such as hypomethylating agents (e.g., azacitidine, decitabine), chemotherapy, or a previous stem‑cell transplant. Simple supportive care like blood transfusions is allowed.
  • You have serious heart problems, such as a heart attack within the last 12 months, moderate‑to‑severe heart failure (New York Heart Association class III or IV), a heart pumping fraction below 40 %, uncontrolled dangerous heart rhythms, or inherited conditions like long‑QT syndrome.
  • You have an active, uncontrolled infection that needs intravenous antibiotics, a serious fungal infection, or uncontrolled COVID‑19 (SARS‑CoV‑2) infection.
  • You have disease involvement in the brain or spinal cord (central nervous system) from the blood cancer.
  • You had a prior allogeneic stem‑cell transplant within the last six months, or you have ongoing graft‑versus‑host disease that requires systemic immunosuppressive medication.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Bexmarilimab

    is an investigational medicine that is given through a vein (intravenous infusion). It is being studied as a possible treatment for higher‑risk myelodysplastic syndromes, a group of blood disorders. In this trial, the drug is combined with another therapy to see if it can improve how well the blood cells work and to assess its safety for patients who have not received prior treatment for this condition. Researchers are looking at how the drug behaves in the body, how it affects the disease, and whether patients can tolerate it well.

  • Azacitidine

    is a chemotherapy‑type medication that is already approved for treating certain blood disorders, including myelodysplastic syndromes. It is given by injection under the skin or into a vein and works by helping abnormal blood‑forming cells mature into normal cells. In this study, azacitidine is used together with the experimental drug Bexmarilimab to determine whether the combination can provide better outcomes for patients who have not yet been treated for higher‑risk myelodysplastic syndromes. The trial evaluates how well the combination works and monitors any side effects.

What is already known about the treatment

  • 0.9% sodium chloride solution for infusion

    This medication is a sterile salt‑water solution that is given through an intravenous (IV) line, allowing it to enter directly into the bloodstream. It is a well‑established product used worldwide to replace fluids and electrolytes, and it is listed in standard medical references as a basic IV fluid. In this trial it serves as a placebo, meaning it does not treat the disease but provides a comparison for the active drug. It belongs to the class of electrolyte solutions.

  • Bexmarilimab

    Bexmarilimab is administered by IV infusion at a dose of 3 mg per kilogram of body weight, delivering the drug straight into the blood. It is an investigational, orphan‑designated monoclonal antibody currently being studied in clinical trials and reported in recent medical literature. The drug is being tested for higher‑risk myelodysplastic syndrome, a blood disorder, and works by blocking the CD47 protein so that the immune system can better recognize and destroy abnormal blood cells. It is classified as a humanized IgG4 monoclonal antibody and an immune‑checkpoint inhibitor.

Investigated diseases

Higher‑risk Myelodysplastic Syndrome (HR‑MDS) - Higher‑risk Myelodysplastic Syndrome (HR‑MDS) is a disorder of the bone marrow in which the production of blood cells is abnormal and insufficient. It is characterized by low counts of red cells, white cells, and platelets, leading to fatigue, increased infections, and easy bruising. Over time, the abnormal marrow cells can become more numerous and the disease may evolve into acute myeloid leukemia. The condition typically worsens gradually, with declining blood counts and increasing marrow abnormalities.
Trial detailsLast updated 17 Nov 2026
Age18+ yearsPhasePhase IITrial ID2026-526706-33-00Protocol codeFP2CLI012Estimated enrolment52 patientsSponsorFaron Pharmaceuticals Oy

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.